GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » Net Change in Cash

Fulgent Genetics (Fulgent Genetics) Net Change in Cash : $18.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Fulgent Genetics's Net Change in Cash for the three months ended in Dec. 2023 was $13.4 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $18.0 Mil.

Fulgent Genetics Net Change in Cash Historical Data

The historical data trend for Fulgent Genetics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Net Change in Cash Chart

Fulgent Genetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.23 75.46 77.47 -85.39 17.97

Fulgent Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.26 -13.33 -7.82 25.73 13.40

Fulgent Genetics Net Change in Cash Calculation

Fulgent Genetics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=27.003+38.898+-47.785+-0.149
=18.0

Fulgent Genetics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=14.933+24.27+-25.951+0.145
=13.4

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics (Fulgent Genetics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » Net Change in Cash
Comparable Companies
TWST OPK CSTL ME ACRS CDNA MYGN LDDD NVTA LAB TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
7F0:Germany 7F0:Germany
Address
4978 Santa Anita Avenue, Temple City, CA, USA, 91780
Website
https://www.fulgentgenetics.com
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Executives
Jian Xie officer: Chief Operating Officer C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Hanlin Gao 10 percent owner, officer: Chief Scientific Officer 4399 SANTA ANITA AVE., EL MONTE CA 91731
Paul Kim officer: CFO and Treasurer 4399 SANTA ANITA AVE, EL MONTE CA 91731
Regina E Groves director 5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post director
Michael Nohaile director C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger director 4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust 10 percent owner 4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh director 100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Ming Hsieh director, 10 percent owner, officer: President and CEO 4399 SANTA ANITA AVE., EL MONTE CA 91731
Fulgent Genetics, Inc. director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay director 6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc. 10 percent owner #6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663

Fulgent Genetics (Fulgent Genetics) Headlines

From GuruFocus

Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting

By Business Wire Business Wire • 05-18-2023

DEADLINE ALERT for FLGT, YSG, BCS, and OLO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

By Value_Insider Value_Insider • 11-21-2022

Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Fulgent Genetics, Inc. (FLGT)

By Value_Insider Value_Insider • 11-21-2022

Fulgent to Participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference

By Business Wire Business Wire • 02-23-2023

FLGT DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Fulgent Genetics, Inc. Investors to Secure Counsel Before Important Monday Deadline in Securities Class Action � FLGT

By Value_Insider Value_Insider • 11-18-2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fulgent Investors of a Lead Plaintiff Deadline of November 21, 2022

By PRNewswire PRNewswire • 11-21-2022

Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting

By Business Wire • 10-25-2023

Fulgent Genetics Inc (FLGT) Reports Q3 2023 Financial Results

By GuruFocus Research • 11-03-2023

FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

By Stock market mentor Stock market mentor • 01-14-2023

Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference

By Business Wire • 11-14-2023